Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | CFD | P00746 | 2/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392086 | 0.88 | KDM4E (0.50) | KDM4EGLAPTGER1MEN1KMT2A | |
| SCHEMBL15105948 | 0.85 | PTGDR2 (0.45) | PTGER1MEN1KMT2APKMDGAT1 | |
| SCHEMBL29333898 | 0.85 | DGAT1 (0.42) | KDM4EPTGER1MEN1KMT2APKM | |
| SCHEMBL29816552 | 0.84 | ALDH1A1 (0.41) | KDM4EGLAALDH1A1CFDMYC | |
| SCHEMBL20107872 | 0.84 | ALDH1A1 (0.41) | KDM4EGLAALDH1A1CFDMYC | |
| SCHEMBL20242123 | 0.83 | ALDH1A1 (0.54) | KDM4EGLAKMT2AALDH1A1CFD | |
| SCHEMBL17908054 | 0.82 | MEN1 (0.55) | KDM4EMEN1KMT2APKMALDH1A1 | |
| SCHEMBL15106217 | 0.82 | GSK3B (0.41) | PTGER1MEN1KMT2APKMDGAT1 | |
| SCHEMBL5236111 | 0.82 | KMT2A (0.46) | KDM4EGLAMEN1KMT2APKM | |
| SCHEMBL5154510 | 0.82 | IDO1 (0.37) | MEN1KMT2APKMDGAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648851-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | Astrazeneca AB (SE) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024149728-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | WO | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11446298-B2 | Pyrimidine derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3625227-B1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-14 | — | — | EP | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | disclosed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| WO-2018210987-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| CN-1264843-C | Pyrazolopyrimidinone derivatives having PDE7 inhibitory action | DAIICHI SUNTORY PHARMACEUTICAL (JP) | 2006-07-19 | — | — | CN | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| CN-1533392-A | Pyrazolopgrimidinone derivatives having PED 7 inhibitory activity | ��һ��������ҩ��ʽ���� | 2004-09-29 | — | — | CN | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 842/4885GLA 4233/4885PTGER1 1/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 1571/4885GLA 4283/4885PTGER1 1/4885 |
| US-11446298-B2 | Pyrimidine derivatives | PTGER1, PTGER4, PTGER2 | KDM4E 1545/4885GLA 3990/4885PTGER1 1/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | KDM4E 1089/4885GLA 4226/4885PTGER1 2/4885 |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | KDM4E 2235/4885GLA 1282/4885PTGER1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.